Juniper Genomics

Genomics and data science Ontario, Canada

| Overview |

 Juniper Genomics has developed a proprietary pipeline using whole-genome sequencing, bioinformatics, and large-scale integrated data platforms to improve the success rate of IVF.

Our Services

Sector

Genomic Testing

Round

Seed Round

Transaction

Capital Raise

Transaction Value

USD 2,700,000

Space

Genomic testing for improved in-vitro fertilization

Milestones

Feasibility of whole-genome approach in 2021

Investors

Xfactor Ventures

Velocity Incubator

Founders

Jeremy Grushcow, PhD/JD Carolyn Quinlan, HBA Lee Shulman, MD

Webste

www.junipergenomics.com

Challenge

Current IVF testing platforms only test for ~50% of causes of IVF

Current IVF testing platforms only test for ~50% of causes of IVF failure/pregnancy loss leading to most patients undergoing 2-3 cycles, leading to high financial and emotional costs for patients.

Solution

A genomic test which screens for all (1000+) known causes of IVF cycle failure/pregnancy loss

Juniper Genomics has developed a genomic test which screens for all (1000+) known causes of IVF cycle failure/pregnancy loss. Furthermore, Juniper seeks to develop a large genetic dataset which will allow for identification of all genetic causes of IVF failure, leading to increased chances of IVF success.

Impact

USD 36B market

By disrupting the incumbent legacy test and improving IVF treatment data, Juniper hopes to enter the ~$36B IVF market.

"AS [ a doctor], I want to provide the most comprehensive and accurate panel of tests available and Juniper is the only offering I have seen that has the potential to deliver on all of these fronts.”

Dr. Meera Shah, MD (Reproductive Endocrinology and Infertility Specialist at Nova IVF, Stanford)

| In the News |

No items found.

Get in touch

Contact us for more information about how we can help you invest in healthcare, biotech, climate tech, or advanced systems.